Search Result

Results for "

Autoimmune diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA synthetase (1) ADC Linker (1) ADC Payload (1) Adenosine Receptor (2) AIM2 (2) Akt (6) ALCAM/CD166 (1) Aminopeptidase (5) AMPK (1) Amyloid-β (4) Angiotensin-converting Enzyme (ACE) (4) Antibiotic (3) Antifolate (4) Apoptosis (21) Aquaporin (2) Arrestin (3) Aryl Hydrocarbon Receptor (1) ASK1 (1) Autophagy (11) Bacterial (7) Bcl-2 Family (1) BCL6 (2) Bcr-Abl (1) Biochemical Assay Reagents (10) BMX Kinase (1) Btk (25) c-Fms (4) C-type Lectin-like Receptors (CTLRs) (1) Calcineurin (1) Calcium Channel (9) Cannabinoid Receptor (1) Caspase (4) Cathepsin (2) CCR (13) CD1 (1) CD19 (1) CD20 (4) CD22 (1) CD28 (2) CD3 (1) CD73 (1) CD74 (1) CDK (3) Chemerin Receptor (1) CHIKV (5) Cholecystokinin Receptor (1) Complement System (7) CTLA-4 (2) CXCR (11) Cyclic GMP-AMP Synthase (5) Cytochrome P450 (2) DAPK (1) Deubiquitinase (2) DGK (2) Dihydroorotate Dehydrogenase (2) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (2) DOCK (1) Dopamine Receptor (2) Drug Derivative (6) Drug Intermediate (3) Drug Isomer (1) Drug Metabolite (1) Drug-Linker Conjugates for ADC (3) E1/E2/E3 Enzyme (1) EBI2/GPR183 (1) EBV (1) Endogenous Metabolite (10) Enterovirus (1) Environmental Pollutants (1) Epigenetic Reader Domain (4) ERK (8) Estrogen Receptor/ERR (3) FABP (1) Fc Receptor (FcR) (7) FLT3 (2) Fungal (1) FXR (2) G Protein-coupled Receptor Kinase (GRK) (2) GCGR (1) Glucocorticoid Receptor (4) GLUT (1) Glycosyltransferase (1) GPR65 (1) GPR84 (1) HCV Protease (1) HDAC (2) Histamine Receptor (4) Histone Acetyltransferase (2) Histone Methyltransferase (3) HIV (1) HSV (1) IFNAR (15) IKK (3) IMPDH (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (5) Insulin Receptor (1) Integrin (6) Interleukin Related (67) IRAK (12) IRE1 (2) Isotope-Labeled Compounds (9) Itk (3) JAK (42) JNK (6) Keap1-Nrf2 (2) Ligands for Target Protein for PROTAC (1) Liposome (4) LPL Receptor (19) LRRK2 (1) LYTACs (1) MAGL (1) MAP3K (1) MAPKAPK2 (MK2) (1) Mas-related G-protein-coupled Receptor (MRGPR) (3) MEK (2) METTL3 (2) MHC (3) Mitochondrial Metabolism (2) MMP (5) Molecular Glues (7) Monoamine Oxidase (2) mRNA (3) mTOR (2) Na+/K+ ATPase (4) nAChR (1) NAMPT (1) Necroptosis (2) NEKs (2) NF-κB (18) NO Synthase (2) NOD-like Receptor (NLR) (5) Notch (1) Nuclear Hormone Receptor 4A/NR4A (1) Orexin Receptor (OX Receptor) (1) Organoid (1) P-glycoprotein (2) p38 MAPK (13) Parasite (7) PARP (1) PD-1/PD-L1 (7) PDHK (2) Phosphatase (4) Phosphodiesterase (PDE) (7) Phospholipase (1) Phosphorylase (2) PI3K (12) PIKfyve (1) Pim (1) PKC (6) Potassium Channel (10) PPAR (1) Prostaglandin Receptor (1) PROTACs (11) Protease Activated Receptor (PAR) (1) Proteasome (7) Protein Arginine Deiminase (7) Pyk2 (1) Pyroptosis (1) Pyruvate Kinase (1) Radionuclide-Drug Conjugates (RDCs) (1) Raf (1) Ras (2) Reactive Oxygen Species (ROS) (4) Reference Standards (14) RET (1) REV-ERB (1) RIP kinase (6) ROCK (2) ROR (17) Salt-inducible Kinase (SIK) (1) SARS-CoV (2) Ser/Thr Protease (3) Src (4) STAT (9) STING (20) Succinate Receptor 1 (1) Syk (3) TAM Receptor (4) TGF-β Receptor (2) TNF Receptor (39) Toll-like Receptor (TLR) (17) Transmembrane Glycoprotein (6) Trk Receptor (1) TRP Channel (5) Tyrosinase (2) VD/VDR (3) VEGFR (1) γ-secretase (2)
By Research Areas:	Cancer (178) Cardiovascular Disease (30) Endocrinology (2) Infection (33) Inflammation/Immunology (508) Metabolic Disease (35) Neurological Disease (59)
Click Chemistry:	Azide (2) Alkynes (2)
Oligonucleotides:	CpG ODNs (2) mRNA (3) Cationic Lipids (3) Cholesterol (1) Interleukin & Receptors (3)

548

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156677

STC-15 4 Publications Verification	METTL3	Cancer
STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases .

HY-12336

NIBR189 3 Publications Verification	EBV EBI2/GPR183	Inflammation/Immunology
NIBR189 is an EBI2 (Epstein-Barr virus-induced gene 2) antagonist. NIBR189 inhibits human and mouse EBI2 with IC₅₀s of 11 and 16 nM, respectively. NIBR189 can be used for the research of autoimmune diseases .

HY-173236

STAT4-IN-1	STAT	Metabolic Disease Inflammation/Immunology Cancer
STAT4-IN-1 is an inhibitor of STAT4 with a K_i of 0.35 μM. STAT4-IN-1 is expected to be used in the research of autoimmune diseases, including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes .

HY-128726

ITK inhibitor 2 2 Publications Verification	Itk	Inflammation/Immunology
ITK inhibitor 2 is a ITK inhibitor with an IC₅₀ of 2 nM. ITK inhibitor 2 is used for research on inflammatory diseases, allergic diseases, autoimmune diseases and transplant rejection .

HY-114181

IRAK4-IN-4 1 Publications Verification	IRAK Cyclic GMP-AMP Synthase	Inflammation/Immunology
IRAK4-IN-4 (Compound 15) is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, with an IC₅₀ of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC₅₀ of 2.1 nM. IRAK4-IN-4 can be used for research of autoimmune diseases .

HY-176566

H-151 Alkyne	STING	Inflammation/Immunology
H-151 Alkyne (Compound H-151-AL) is a selective STING (Stimulator of interferon genes) inhibitor. H-151 Alkyne is promising for research of autoimmune diseases such as systemic lupus erythematosus, scleroderma, and autoinflammatory diseases .

HY-168624

VAV1 degrader-2	Molecular Glues	Inflammation/Immunology
VAV1 degrader-2 is a molecular glue degrader based on targeting Vav guanine nucleotide exchange factor 1 (VAV 1) with a DC₅₀ of 4.41 nM. VAV1 degrader-2 can be used in the study of inflammatory and autoimmune diseases .

HY-174905

Quecitinib QY201	JAK Cytochrome P450	Inflammation/Immunology
Quecitinib (QY201) is an orally active JAK1/TYK2 dual inhibitor. Quecitinib is also a substrate of cytochrome P450 3A and is mainly metabolized to mono-oxide and glucuronidation products. Quecitinib has favorable pharmacokinetic properties as well as safety. Quecitinib can be used in the research of atopic dermatitis and other autoimmune diseases .

HY-107371

6-Bromo-2-hydroxy-3-methoxybenzaldehyde NSC95682	IRE1	Inflammation/Immunology Cancer
6-Bromo-2-hydroxy-3-methoxybenzaldehyde (NSC95682) (Compound 3-5) is a selective and potent IRE-1α inhibitor with an IC₅₀ value of 0.08 μM. 6-Bromo-2-hydroxy-3-methoxybenzaldehyde can be used for research on diseases associated with the unfolded protein response (UPR), such as cancer and autoimmune diseases .

HY-P99563

Tibulizumab LY 3090106	TNF Receptor Interleukin Related	Inflammation/Immunology
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research .

HY-P99190

Eldelumab BMS-936557; MDX-1100	CXCR	Inflammation/Immunology
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .

HY-153245

JNJ-64264681	Btk	Inflammation/Immunology Cancer
JNJ-64264681 is a potent, orally active, selective and irreversible covalent BTK inhibitor. JNJ-64264681 exhibits good pharmacokinetic characteristics and can be used for cancer and autoimmune diseases research .

HY-137553

β-Aminoarteether SM934 free base	NOD-like Receptor (NLR)	Inflammation/Immunology
β-Aminoarteether (SM934 free base) is an Artemisinin derivative with orally active. β-Aminoarteether can be used for inflammation and autoimmune disease research, such as lupus diseases .

HY-144619

TLR7/8 antagonist 2	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 antagonist 2 (Compound 15) is a potent and orally active agonist of TLR7/8 with IC₅₀s of 4.9 and 0.6 nM, respectively. Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. TLR7/8 antagonist 2 has the potential for the research of autoimmune diseases .

HY-149006

CK156	DAPK	Inflammation/Immunology Cancer
CK156, a chemical probe, is a highly selective death-associated protein kinase (DAPK) inhibitor with IC₅₀s of 182 nM,34 μM, and 39 μM in the DRAK1 NanoBRET assay for DRAK1, CK2a1, and CK2a2, respectively. CK156 can be used for the research of autoimmune and inflammatory diseases .

HY-148141

JPE-1375 4 Publications Verification	Complement System	Inflammation/Immunology
JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC₅₀=6.9 μM) and reduces TNF levels (EC₅₀=4.5 μM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases .

HY-B1084

Cinoctramide	Drug Intermediate	Others
Cinoctramide is an intermediate of pharmaceutical synthesis. Cinoctramide can be used for the research of autoimmune diseases .

HY-46225

DEX-maleimide	Drug Intermediate	Inflammation/Immunology
DEX-maleimide is a coupling agent that can be used to synthesize conjugates containing single-domain antibodies (VHH) conjugated with antigens and anti-inflammatory agents. DEX-maleimide can be used for research on autoimmune diseases .

HY-P5963

Lib2-1	Interleukin Related	Inflammation/Immunology
Lib2-1, a macrocyclic peptide, is an IL-17C/IL-17RE interaction inhibitor. Lib2-1 can be used for autoimmune and inflammatory diseases research .

HY-176778

BDM88951	Aminopeptidase	Inflammation/Immunology Cancer
BDM88951 (Compound 4 d) is a selective ERAP2 inhibitor with an IC₅₀ of 19  nM. BDM88951 significantly inhibits antigen presentation. BDM88951 can be used for autoimmune diseases and cancers research .

HY-174136

STING Degrader-2	STING IFNAR	Inflammation/Immunology
STING Degrader-2 is an orally active STING degrader that promotes proteasome-independent degradation of STING. STING Degrader-2 inhibits cGAMP-induced STING activation, suppresses STING oligomerization, and inhibits phosphorylation of STING and interferon regulatory factor 3 (IRF3). STING Degrader-2 reduces serum IFN-β and CXCL-10 levels in a cGAMP-induced autoimmune disease mouse model. STING Degrader-2 can be used for the research of autoimmune diseases .

HY-153322

ITK degrader 2	PROTACs Itk	Inflammation/Immunology Cancer
ITK degrader 2 is an orally active ITK PROTAC degrader with a DC₅₀ < 0.001 nM. ITK degrader 2 degrades ITK via the ubiquitin-proteasome pathway. ITK degrader 2 can be used in the research of cancer, autoimmune diseases and inflammatory diseases .

HY-P991532

AT002 MEMD; EJ212/007-Cl2-5	ALCAM/CD166	Inflammation/Immunology Cancer
AT002 (CBAS-173, EJ212/007-Cl2-5) is a recombinant human IgG1 monoclonal antibody. AT002 targets the cell surface protein activated leukocyte adhesion molecule (ALCAM)/CD166. AT002 can be used in the research of cancer, autoimmune diseases and inflammatory diseases.

HY-P991682

Emzotamig	TNF Receptor	Inflammation/Immunology
Emzotamig is a monoclonal antibody inhibitor targeting tumor necrosis factor (TNF). Emzotamig is promising for research of autoimmune diseases associated with TNF overexpression, such as rheumatoid arthritis and ankylosing spondylitis .

HY-P991658

Gerilimzumab ARGX-109; GB224; RYI-008	Interleukin Related	Inflammation/Immunology
Gerilimzumab (GB224) is a humanized monoclonal antibody inhibitor targeting interleukin-6 (IL-6). Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis .

HY-P4040

Ac-D-DGla-LI-Cha-C	HCV Protease	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases .

HY-N11286

Tridocosahexaenoylglycerol TG-DHA; Meganol D	Others	Neurological Disease Metabolic Disease Inflammation/Immunology
Tridocosahexaenoylglycerol (TG-DHA) is an orally active dietary supplement that improves autoimmune encephalomyelitis in mice. Tridocosahexaenoylglycerol shows beneficial effects on neurodegenerative diseases and also improves macular function in diabetic retinopathy. Tridocosahexaenoylglycerol can be used for research on neurological diseases, inflammatory immune diseases, and metabolic diseases .

HY-142934

RORγt inhibitor 2	ROR	Inflammation/Immunology Cancer
RORγt inhibitor 2 (Compound 119) is a potent RORγt inhibitor with an IC₅₀ of 9.2 nM. RORγt inhibitor 2 can be used for the research of cancer, inflammation or autoimmune diseases mediated by RORγt .

HY-144882

(R)-HH2853	Histone Methyltransferase	Inflammation/Immunology Cancer
(R)-HH2853 is a mutant EZH2 inhibitor with an IC₅₀ of <100 nM for EZH2-Y641F. (R)-HH2853 can be used for cancer and autoimmune diseases (WO2018045971A1; compound 201) .

HY-W409806

Cholesterylamine	Liposome	Inflammation/Immunology
Cholesterylamine is a cationic lipid. Cholesterylamine can be added to the PLGA to prepare PLGA particle having surface charge. Cholesterylamine can be used for drug delivery. Cholesterylamine can be used for autoimmune diseases and allergy research .

HY-177130S

Socrodeucitinib	JAK	Inflammation/Immunology
Socrodeucitinib (Compound Example 58) is an orally active and selective tyrosine kinase 2 (TYK2) inhibitor with an IC₅₀ value of 1.41 nM. Socrodeucitinib exerts anti-inflammatory activity by inhibiting TYK2-mediated cytokine signaling pathways and reducing the secretion of inflammatory factors. Socrodeucitinib is promising for research of autoimmune diseases such as psoriasis and inflammatory diseases .

HY-175365

GCS-12–6	CD1	Inflammation/Immunology
GCS-12–6 is a potent Th2-selective NKT cell agonist targeting CD1d protein. GCS-12–6 is promising for research of autoimmune diseases (e.g., inflammatory bowel disease, multiple sclerosis) .

HY-137553A

β-Aminoarteether maleate SM934	NOD-like Receptor (NLR)	Inflammation/Immunology
β-Aminoarteether maleate (SM934) is an Artemisinin derivative with orally active. β-Aminoarteether maleate can be used for inflammation and autoimmune disease research, such as lupus diseases .

HY-14976

CS-0777	LPL Receptor	Inflammation/Immunology
CS-0777 is a selective, orally active sphingosine 1-phosphate receptor-1 modulator. CS-0777 can be used in the research of autoimmune diseases .

HY-178491

S1PR1 agonist 3	LPL Receptor	Inflammation/Immunology
S1PR1 agonist 3 (Compound Y18) is a highly selective S1PR1 receptor agonist (EC₅₀=0.98 nM). S1PR1 agonist 3 is promising for research of autoimmune diseases such as multiple sclerosis and ulcerative colitis .

HY-143485

IRAK4-IN-9	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-9 (compound 73) is a potent IRAK4 inhibitor with an IC₅₀ of 1.5 nM. IRAK4-IN-9 blocks MyD88 dependent signaling. IRAK4-IN-9 has the potential for the research of inflammatory diseases, autoimmune diseases, and cancer .

HY-148543

FC-99	Transmembrane Glycoprotein	Inflammation/Immunology
FC-99 is a Tenascin-C (TN-C) inhibitor with anti-inflammatory effects. FC-99 reduces inflammatory responses in rheumatoid arthritis (RA). FC-99 is promising for research of autoimmune diseases, particularly rheumatoid arthritis .

HY-147584

BTK-IN-14	Btk	Inflammation/Immunology Cancer
BTK-IN-14 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1) .

HY-120457

WYE-151650	JAK STAT	Inflammation/Immunology
WYE-151650 is a selective JAK-3 inhibitor. WYE-151650 suppresses IL-2-induced STAT-5 phosphorylation and cell proliferation mediated by JAK-3. WYE-151650 is promising for research of autoimmune diseases .

HY-174843

IRAK4-IN-32	IRAK	Inflammation/Immunology
IRAK4-IN-32 (Compound 10) is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an enzymatic IC₅₀ value of 18.86 nM and a cellular IC₅₀ value of 6.19 nM. IRAK4-IN-32 is promising for research of inflammatory and autoimmune diseases .

HY-138281

Complement factor D-IN-2	Complement System	Inflammation/Immunology
Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases .

HY-P991596

ANB004	Interleukin Related	Inflammation/Immunology
ANB004 is a humanized monoclonal antibody inhibitor, targeting IL-17. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research .

HY-156592

ROCK2-IN-6	ROCK	Inflammation/Immunology
ROCK2-IN-6 (Comp A) is a selective ROCK2 inhibitor, can be used for ROCK mediated diseases, autoimmune diseases and inflammation research .

HY-P991275

CNTO4088	Interleukin Related	Inflammation/Immunology
CNTO4088 is a monoclonal antibody inhibitor targeting interleukin-23 (IL-23). CNTO4088 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .

HY-156556

c-Fms-IN-14	c-Fms	Inflammation/Immunology Cancer
c-Fms-IN-14 (Example 76) is a c-Fms inhibitor with an IC₅₀ value of 4 nM. c-Fms-IN-14 can be used for research of cancer and autoimmune diseases .

HY-179609

C201-0243	Fc Receptor (FcR)	Inflammation/Immunology
C201-0243 is a FcRn antagonist. C201-0243 exhibits antagonistic activity against IgG-FcRn binding with an IC₅₀ of 3.439 nM. C201-0243 can be used in the research of IgG-mediated autoimmune diseases .

HY-160216A

RIPK1-IN-18 sulfate hydrate	RIP kinase	Inflammation/Immunology
RIPK1-IN-18 sulfate hydrate is a potent RIPK1 inhibitor that can be used in autoimmune diseases research (NZ748385A; compound i) .

HY-121662

Lenaldekar LDK	Apoptosis	Inflammation/Immunology Cancer
Lenaldekar (LDK) inhibits human and murine T-cell expansiomn. Lenaldekar inhibits autoimmune T cell response. Lenaldekar also induces cancer cell apoptosis. Lenaldekar can be used for T-cell mediated autoimmune diseases research .

HY-P991263

SCH-900117	Interleukin Related	Inflammation/Immunology
SCH-900117 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .

HY-156565

S1P1 agonist 6	LPL Receptor	Inflammation/Immunology
S1P1 agonist 6 (Compound I) is a S1P1 agonist that reduces autoimmune ability by blocking the transportation of lymphocytes. S1P1 agonist 6 can be used as an immunosuppressive agent in the study of various autoimmune diseases research .

Cat. No.	Product Name

HY-L156

Autoimmune Disease Compound Library

958 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 958 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

HY-L164

Serine/Threonine Kinase Inhibitor Library

2,162 compounds

Protein serine/threonine kinases (PSKs) are protein kinases that use ATP as a high-energy donor molecule to transfer phosphate groups to serine/threonine residues of target protein. As an important signal transduction regulator, serine/threonine kinases can affect the function of target proteins by disrupting enzyme activity or binding of target proteins to other proteins. Serine/threonine kinases are involved in the regulation of immune response, cell proliferation, differentiation, apoptosis and other physiological processes. Serine/threonine kinase inhibitors are an important class of compounds that have been widely studied in cancer, chronic inflammation, autoimmune diseases, aging and other diseases.

MCE designs a unique collection of 2,162 serine/threonine kinase inhibitors, mainly targeting the receptor PKA, Akt, PKC, MAPK/ERK, etc, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases, anti-autoimmune diseases and anti-aging compounds.

HY-L161

Cytokine Inhibitors Library

1,332 compounds

Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases.

MCE designs a unique collection of 1,332 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.

HY-L210

Anti-Rheumatic Arthritis Compound Library

1,883 compounds

Rheumatoid Arthritis (RA) is a autoimmune disease characterized by persistent joint inflammation. The pathology of RA includes immune cell infiltration, synovial lining proliferation, pannus formation, and the destruction of joint cartilage and bone, which is highly disabling. Due to long-term chronic inflammation, RA not only severely affects the quality of life of patients but can also damage multiple organs, leading to lung diseases, cardiovascular diseases, and malignant tumors. The pathogenesis of RA is complex, involving genetic, environmental, and immune factors. With the advancement of high-throughput screening technology, screening for compounds targeting JAK, CCR, MEK, MMP targets may contribute to the development of more effective drugs against Rheumatoid Arthritis (RA).

MCE has collected 1,883 small molecule compounds with definite or potential anti-rheumatoid arthritis activity. This library is of significant value for researching the anti-RA drugs.

HY-L175

Inflammasomes related Compound Library

163 compounds

Inflammasomes are classic pattern recognition receptors for natural immune responses. Inflammasomes are polymeric protein complexes that regulate inflammatory responses and pyrolytic cell death, thereby exerting the host's defense against microorganisms. Inflammasomes sensors are associated with adapter proteins, activating inflammatory caspase-1, releasing inflammatory cytokines and inducing cell death, endowing the host with defense against pathogens. NLRP1, NLRP3, NLRC4, AIM2, and pyrin are considered typical inflammasomes because they convert cysteine asparaginase-1 into catalytically active capsaicin-1. In addition to infectious diseases, the importance of inflammasomes is also related to various clinical diseases, such as autoimmune diseases, neurodegeneration and metabolic disorders, and the development of cancer. Therefore, it is necessary to strictly regulate the activation and function of inflammasomes to avoid accidental host tissue damage while inducing pathogens to kill the inflammatory response.

MCE designs a unique collection of 163 inflammasomes related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

HY-L007

Immunology/Inflammation Compound Library

7,846 compounds

The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.

MCE designs a unique collection of 7,846 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

HY-L237

Pattern Recognition Receptors Library

313 compounds

Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions.

MCE has cataloged 313 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.

HY-L024

Histone Modification Research Compound Library

904 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 904 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

HY-L014

NF-κB Signaling Compound Library

1,670 compounds

Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.

MCE owns a unique collection of 1,670 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

HY-L934

CRBN Ligand Library

125 compounds

CRBN, namely cereblon, is the substrate recognition subunit of the E3 ubiquitin ligase complex in the ubiquitin-proteasome system. A CRBN ligand library refers to a collection of numerous fragments that can specifically bind to the CRBN protein.

These ligands are mostly designed based on validated CRBN-binding warheads and modified through AI-driven molecular generation optimization systems. They not only include classic lenalidomide-derived structures but also cover novel non-lenalidomide scaffolds. After drug-likeness filtering, these ligands exhibit structural diversity and favorable druggable properties. They can be further optimized and modified to facilitate the development of novel molecular glue degraders, accelerate the discovery of molecular glues that induce interactions between CRBN and new substrate proteins, and enable the exploration of novel CRBN substrates for identifying previously unknown CRBN-binding proteins.

MCE compiles 125 fragments that can specifically bind to the CRBN protein, with molecular weights ranging from 200 to 500. Compounds developed based on the library ligands target multiple disease targets such as cancer and autoimmune diseases, further advancing the development of Molecular Glues and PROTACs therapeutic agents.

Cat. No.	Product Name	Type

HY-Y0344D

Sodium chloride, for cell culture

3 Publications Verification

Halite, for cell culture

Biochemical Assay Reagents

Sodium chloride, for cell culture is an orally active salt. Sodium chloride, for cell culture induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, for cell culture enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, for cell culture drives autoimmune disease by the induction of pathogenic Th17 cells .

HY-14519B

Methotrexate hydrate Maximum Cited Publications 76 Publications Verification Amethopterin hydrate; CL14377 hydrate; WR19039 hydrate	Biochemical Assay Reagents
Methotrexate hydrate is a substance that affects cell growth and division. It is commonly used to fight certain diseases, especially cancer and autoimmune diseases. It works by inhibiting the process by which cells synthesize DNA.

HY-Y0344J

Sodium chloride, for molecular biology

3 Publications Verification

Halite, for molecular biology

Biochemical Assay Reagents

Sodium chloride is an orally active salt. Sodium chloride induces the expression of ATP1A1. Sodium chloride induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride drives autoimmune disease by the induction of pathogenic Th17 cells .

HY-Y0344I

Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al

3 Publications Verification

Halite, meets analytical specification of Ph. Eur. BP USP

Biochemical Assay Reagents

Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt is an orally active salt. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt induces the expression of ATP1A1. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt drives autoimmune disease by the induction of pathogenic Th17 cells .

HY-125139

omega-3 Arachidonic acid ethyl ester, in ethanol, 98%

ω-3 Arachidonic acid ethyl ester, in ethanol, 98%; (all-Z)-8,11,14,17-Eicosatetraenoic acid ethyl ester, in ethanol, 98%

Biochemical Assay Reagents

omega-3 Arachidonic acid ethyl ester, in ethanol, 98% is a rare polyunsaturated fatty acid found in very small amounts in dietary sources. Omega-3 fatty acids are known to be essential for the growth and development of infants, and they protect against heart disease, blood clots, high blood pressure, and inflammatory and autoimmune diseases. In human platelet membranes, omega-3 arachidonic acid inhibits arachidonyl-CoA synthetase with a Ki of 14 μM. It also inhibits arachidonoyl-CoA synthetase in calf brain extract with an IC50 of approximately 5 μM. Omega-3 ethyl arachidonate is the more lipophilic form of the free acid.

HY-W355779

Gliadins Tyrosylprolylglutaminylprolylglutamine	Biochemical Assay Reagents
Gliadins (Tyrosylprolylglutaminylprolylglutamine) comprise a family of glutamine- and proline-rich monomeric proteins that plays an role in autoimmune disease, such as celiac disease .

HY-Y0344H

Sodium chloride, United States Pharmacopeia (USP) Reference Standard

Halite (Pharmaceutical primary standard, USP)

Biochemical Assay Reagents

Sodium chloride, United States Pharmacopeia (USP) Reference Standard is an orally active salt. Sodium chloride, United States Pharmacopeia (USP) Reference Standard induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, United States Pharmacopeia (USP) Reference Standard enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, United States Pharmacopeia (USP) Reference Standard drives autoimmune disease by the induction of pathogenic Th17 cells .

Cat. No.	Product Name	Target	Research Area

HY-P1240

MOG (35-55) mouse, rat Maximum Cited Publications 9 Publications Verification Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
MOG (35-55) mouse, rat (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) is a minor component of CNS myelin. MOG (35-55) mouse, rat has encephalitogenic activity and induces T cell proliferative. MOG (35-55) mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) mouse, rat (MOG (35-55)) can be used for experimental autoimmune encephalomyelitis (EAE) modeling .

HY-P3252A

Pegcetacoplan acetate 1 Publications Verification	Complement System	Inflammation/Immunology
Pegcetacoplan acetate is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD) .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P1240A

MOG (35-55) TFA Maximum Cited Publications 9 Publications Verification Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
MOG (35-55) (MOG (35-55)) TFA is a minor component of CNS myelin. MOG (35-55) (TFA) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (TFA) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (TFA) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (MOG (35-55)) TFA can be used for experimental autoimmune encephalomyelitis (EAE) modeling .

HY-P5766

AChRα(97-116)	nAChR
AChRα(97-116) is a synthetic peptide corresponding to the 97-116 region of the rat acetylcholine receptor α-subunit, and also an inducer of autoimmune diseases. AChRα(97-116) can be used in studies related to experimental autoimmune myasthenia gravis .

HY-P1680

Astin C Asterin	STING HSV	Infection Inflammation/Immunology Cancer
Astin C (Asterin) is a cyclopeptide that can be extracted from Aster tataricus. Astin C has anti-inflammatory and anti-cancer activities. Astin C can specifically inhibit the cGAS-STING signaling pathway, block the recruitment of IRF3 to the STING signalosome, and thus inhibit the innate inflammatory response. Astin C can be used in the research of autoimmune diseases and cancers .

HY-P1240B

MOG (35-55) acetate Maximum Cited Publications 9 Publications Verification Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate	Peptides	Neurological Disease Inflammation/Immunology
MOG (35-55) (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) acetate is a minor component of CNS myelin. MOG (35-55) (acetate) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (acetate) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (acetate) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) acetate can be used for experimental autoimmune encephalomyelitis (EAE) modeling .

HY-P1587

IRBP (1-20), human	MHC	Inflammation/Immunology
IRBP (1-20), human contains a major epitope for the H-2 ^b haplotype. IRBP (1-20), human induces experimental autoimmune uveoretinitis (EAU) in H-2 ^b mice .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P10019

Pegsebrenatide NLY01	GCGR	Neurological Disease Inflammation/Immunology
Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant GLP-1R agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension . Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis . Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis .

HY-P3012

Cathepsin G	Cathepsin ERK p38 MAPK PKC Protease Activated Receptor (PAR) MMP	Inflammation/Immunology
Cathepsin G is a pH-dependent serine protease. Cathepsin G hydrolyzes diverse synthetic and protein substrates and remodels extracellular matrix. Cathepsin G exerts immunomodulatory effects via recruiting phagocytes, enhancing T cell motility, activating ERK1/2 and p38 MAPK signaling, and mediating PKCζ membrane translocation. Cathepsin G regulates inflammatory responses by cleaving inflammatory mediators. Cathepsin G participates in vascular regulation by converting angiotensin I to angiotensin II. Cathepsin G induces PAR4-dependent platelet activation, facilitates platelet-neutrophil aggregation, and mediates VITT-related NETosis, thrombus formation. Cathepsin G can be used for the research of immune thrombotic thrombocytopenia, cardiovascular disease, and select autoimmune and inflammatory diseases .

HY-P5963

Lib2-1	Interleukin Related	Inflammation/Immunology
Lib2-1, a macrocyclic peptide, is an IL-17C/IL-17RE interaction inhibitor. Lib2-1 can be used for autoimmune and inflammatory diseases research .

HY-P10441A

S-palm P0(180–199) TFA 1 Publications Verification	Peptides	Inflammation/Immunology
S-palm P0(180–199) (TFA) is a peptide that enhances MHC II-restricted responses. S-palm P0(180–199) (TFA) can be used to establish models of chronic inflammatory demyelinating polyneuropathy (CIDP) and chronic experimental autoimmune neuritis (c-EAN). S-palm P0(180–199) (TFA) is used for studying autoimmune-mediated neuroinflammatory diseases .

HY-P1587A

IRBP (1-20), human TFA	Peptides	Inflammation/Immunology
IRBP (1-20), human TFA contains a major epitope for the H-2 ^b haplotype. IRBP (1-20), human TFA induces experimental autoimmune uveoretinitis (EAU) in H-2 ^b mice .

HY-P10935A

Amilo-5MER TFA 5-MP TFA	Amyloid-β Interleukin Related	Inflammation/Immunology
Amilo-5MER (5-MP) TFA is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER TFA specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER TFA reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER TFA is promising for research of autoimmune diseases and chronic inflammatory diseases .

HY-P5121A

γ-Fibrinogen 377-395 TFA	Peptides	Cardiovascular Disease
γ-Fibrinogen377-395 TFA is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 TFA blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 TFA can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation .

HY-P4040

Ac-D-DGla-LI-Cha-C	HCV Protease	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases .

HY-P1409A

ADWX 1 TFA 1 Publications Verification	Potassium Channel	Inflammation/Immunology
ADWX 1 TFA is a new peptide inhibitor that is potent and selective for Kv1.3 with an IC₅₀ value of 1.89 pM. ADWX 1 inhibits Kv1.3 channel activity specifically to inhibit both the initial calcium signaling and NF-κB activation. ADWX 1 TFA ameliorates the disease in rats of experimental autoimmune encephalomyelitis (EAE) models. ADWX 1 TFA can be used to study T cell-mediated autoimmune diseases .

HY-P10512

BDC2.5 mimotope	Peptides	Others
BDC2.5 mimotope is a potent antigen-mimicking peptide that can activate CD4+ T cell populations that have the same antigen recognition properties as BDC2.5 cells. BDC2.5 mimotope can be used to study the prevention or treatment of type 1 diabetes by targeting specific T cell populations .

HY-P5488

BDC2.5 Mimotope 1040-63	Peptides	Others
BDC2.5 Mimotope 1040-63 is a biological active peptide. (The TCR transgenic model (BDC2.5) mimitope was used in type 1 diabetes (T1D) study. T1D is an autoimmune disease in which T cells mediate damage to pancreatic islet b cells. T1D is caused by autoreactive T cell destruction of insulin-producing cells. BDC2.5 mimotope was utilized to support the study on antigen presentation of antigenic peptides to islet autoantigen-specific T cells.)

HY-P10497

EBV BZLF1 (190-197)	Bacterial	Infection Inflammation/Immunology
EBV BZLF1 (190-197) is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) can be used to study autoimmune diseases .

HY-P10497A

EBV BZLF1 (190-197) TFA	Bacterial	Infection Inflammation/Immunology
EBV BZLF1 (190-197) TFA is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) TFA is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) TFA are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) TFA can be used to study autoimmune diseases .

HY-P10935

Amilo-5MER 5-MP	Amyloid-β Interleukin Related	Inflammation/Immunology
Amilo-5MER (5-MP) is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER is promising for research of autoimmune diseases and chronic inflammatory diseases .

HY-P11553

ECL1i	CCR	Inflammation/Immunology
ECL1i is an allosteric, selective CCR2 inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-P11553A

ECL1i TFA	CCR	Infection Inflammation/Immunology
ECL1i TFA is an allosteric, selective CCR2 inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-P3248

J5 peptide Myelin basic protein (85-99) antagonist	Biochemical Assay Reagents	Inflammation/Immunology
J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP_85-99 to HLA-DR2. J5 peptide alleviates PLP_139-151/MBP_85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .

HY-P5377

Abz-HPGGPQ-EDDnp Cathepsin K substrate	Ser/Thr Protease	Others
Abz-HPGGPQ-EDDnp (Cathepsin K substrate) is a biological active peptide. (Cathepsins are a class of globular lysosomal proteases, playing a vital role in mammalian cellular turnover. They degrade polypeptides and are distinguished by their substrate specificities. Cathepsin K is the lysosomal cysteine protease involved in bone remodeling and resorption. It has potential as a drug target in autoimmune diseases and osteoporosis.This FRET peptide can be used to monitor selectively cathepsin K activity in physiological fluids and cell lysates. Abz-HPGGPQ-EDDnp [where Abz represents o-aminobenzoic acid and EDDnp represents N -(2, 4-dinitrophenyl)-ethylenediamine], a substrate initially developed for trypanosomal enzymes, is efficiently cleaved at the Gly-Gly bond by cathepsin K. This peptide is resistant to hydrolysis by cathepsins B, F, H, L, S and V, Ex/Em=340 nm/420 nm.)

HY-P1409

ADWX 1	Potassium Channel	Inflammation/Immunology
ADWX 1 is a new peptide inhibitor that is potent and selective for Kv1.3 with an IC₅₀ value of 1.89 pM. ADWX 1 inhibits Kv1.3 channel activity specifically to inhibit both the initial calcium signaling and NF-κB activation. ADWX 1 ameliorates the disease in rats of experimental autoimmune encephalomyelitis (EAE) models. ADWX 1 can be used to study T cell-mediated autoimmune diseases .

HY-120794

SC-67655	TNF Receptor	Inflammation/Immunology
SC 67655 is a potent and stable pentapeptide MHC class II haplotype DR4 (DR4 Dw4 or DRB 1"0401) ligand with an IC₅₀ of 50 nM. SC 67655 can be used for the study of autoimmune diseases .

HY-P10572

HG1 Toxin	Ser/Thr Protease Potassium Channel	Inflammation/Immunology Endocrinology
HG1 Toxin is a peptide found in the venom of the scorpion Heterometrus fulvipes, which has the activity of inhibiting potassium channel Kv1.3. HG1 Toxin also has the activity of inhibiting trypsin (K_i=107 nM) and can be used in the study of autoimmune diseases .

HY-P5853

Aam-KTX	Potassium Channel	Inflammation/Immunology
Aam-KTX is a K_v channel inhibitor with IC₅₀ values of 1.1 nM and >750 nM for K_v1.3 and K_v1.1, respectively. Aam-KTX is a toxic peptide obtained from the venom of the scorpion Mesobuthus eupeus. Aam-KTX has potential in autoimmune diseases research .

HY-P10525

MBP Ac1-9 (4Y)	Peptides	Neurological Disease
MBP Ac1-9 (4Y) is a synthetic peptide derived from a fragment of myelin basic protein (MBP) that has undergone specific chemical modifications. MBP Ac1-9 (4Y) is able to form a complex with the MHC class II molecule I-Au and activate specific T cell receptor (TCR), thus playing a role in the pathogenesis of experimental autoimmune encephalomyelitis (EAE). MBP Ac1-9 (4Y) can be used to study autoimmune diseases, especially those involving the central nervous system, such as multiple sclerosis .

HY-P10315

[Gln144]-PLP (139-151) Q144-PLP(139-151)	Transmembrane Glycoprotein	Others
[Gln144]-PLP (139-151) is an experimental antigen used to study T cells respond to both autoantigens and cross-reactive non-autoantigens. [Gln144]-PLP (139-151) activates T cells by binding to T-cell Receptor (TCR), which triggers an immune response. [Gln144]-PLP (139-151) can be used to study the regulation of autoimmune diseases .

HY-P10937

AQP4 (205-215)	Aquaporin	Inflammation/Immunology
AQP4 (205-215) is a fragment of Aquaporin-4 (AQP4). AQP4 is a neuromyelitis optica autoantigen that is upregulated and presented in B cells after engagement of CD40. AQP4 is associated with autoimmune inflammatory diseases of the central nervous system (CNS), neuromyelitis optica (NMO) .

HY-P10937A

AQP4 (205-215) TFA	Aquaporin	Inflammation/Immunology
AQP4 (205-215) TFA is a fragment of Aquaporin-4 (AQP4). AQP4 is a neuromyelitis optica autoantigen that is upregulated and presented in B cells after engagement of CD40. AQP4 is associated with autoimmune inflammatory diseases of the central nervous system (CNS), neuromyelitis optica (NMO) .

HY-P3446A

Big Gastrin I (human) TFA	Cholecystokinin Receptor	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Big Gastrin I, human (TFA) is a gastrointestinal hormone consisting of 34 amino acids. Big Gastrin I, human (TFA) can be used as a potential substance for the study of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurological diseases or cardiovascular diseases .

HY-P10469

NBD-2	NF-κB	Inflammation/Immunology Cancer
NBD-2 is an inhibitor of the NEMO-IKKα/β interaction in the NF-κB signaling pathway. NBD-2 specifically inhibits the typical NF-κB signaling pathway in vitro and in vivo, reducing the inflammatory response in lipopolysaccharide (LPS) induced acute lung injury (ALI). NBD-2 exhibits significant anti-inflammatory activity. NBD-2 can be used to study diseases related to NF-κB signaling pathway, including autoimmune diseases, cancer, etc .

HY-P10522

MBP Ac1-9	Peptides	Others
MBP Ac1-9 refers to a peptide fragment of myelin basic protein (MBP). MBP Ac1-9 is an immunodominant epitope in the experimental autoimmune encephalomyelitis (EAE) model, which can induce T cell immune response and lead to pathological changes similar to multiple sclerosis. MBP Ac1-9 can be used to study T cell activation and autoimmune response .

HY-P5870

KTX-Sp2	Potassium Channel	Inflammation/Immunology
KTX-Sp2 is a potassium channel toxin. KTX-Sp2 effectively blocks three types of exogenous voltage-gated potassium channels: Kv1.1, Kv1.2 and Kv1.3. Ktx-Sp2 inhibits endogenous Kv1.3 and suppresses Ca ²⁺ signaling in Jurkat T cells. Ktx-Sp2 inhibits IL-2 secretion from activated Jurkat T cells .

HY-P10982

SjDX5-53	Toll-like Receptor (TLR)	Inflammation/Immunology
SjDX5-53 is a selective TLR2 inducer derived from a 3 kDa peptide from Schistosoma japonicum eggs. SjDX5-53 inhibits inflammatory Th1 and Th17 responses by inducing tolerogenic dendritic cells (tolDCs) and promoting the generation of regulatory T cells (Tregs) and their suppressive capacity. SjDX5-53 is primarily used in the treatment of autoimmune and inflammatory diseases such as colitis and psoriasis .

HY-P5121

γ-Fibrinogen 377-395	Peptides	Cardiovascular Disease
γ-Fibrinogen377-395 is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation .

HY-P10492

Tregitope 289	Peptides	Others Metabolic Disease
Tregitope 289 is a peptide derived from the Fc region of immunoglobulin G (IgG) and is a highly conserved T cell epitope that stimulates the expansion of natural regulatory T cells. Co-delivery of Tregitope 289 with type 1 diabetes (T1D) antigens delays the development of hyperglycemia and reduces the incidence of diabetes in the NOD mouse model. Tregitope 289 can be used to study T1D and other autoimmune diseases .

HY-P11014

SjDX5-53 control peptide	Toll-like Receptor (TLR)	Inflammation/Immunology
SjDX5-53 control peptide is a control peptide of the TLR2 activator SjDX5-53 (HY-P10982) that does not target a specific receptor and does not modulate regulatory T cells (Tregs) or dendritic cells. SjDX5-53 control peptide can be used to exclude nonspecific effects and help verify the specific role of SjDX5-53 in inducing Tregs and alleviating autoimmune diseases. SjDX5-53 control peptide is used in the study of autoimmune diseases such as colitis and psoriasis .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9913

Rituximab 10+ Cited Publications Anti-Human CD20 type I, Chimeric Antibody; HSDB 7455; IDEC-C2B8	Radionuclide-Drug Conjugates (RDCs) CD20	Inflammation/Immunology Cancer
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

HY-P9970

Infliximab Maximum Cited Publications 27 Publications Verification Avakine; CT-P13; SB2; TA-650	TNF Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research . The component ratio of this product is Active ingredient : Excipients = 9 : 47.

HY-P9913A

Rituximab (anti-CD20) 10+ Cited Publications	CD20	Inflammation/Immunology Cancer
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .

HY-108829

Abatacept 1 Publications Verification CTLA4lg; BMS-188667	CTLA-4	Inflammation/Immunology Cancer
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .

HY-P9952

Belimumab 5 Publications Verification LymphoStat B	TNF Receptor CD20	Inflammation/Immunology Cancer
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research . The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.

HY-P99037

Nipocalimab 3 Publications Verification M281	Fc Receptor (FcR)	Inflammation/Immunology
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .

HY-P99568

Telitacicept RC18	TNF Receptor	Inflammation/Immunology
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease . The component ratio of this product is Active ingredient : Excipients = 1: 0.5-1: 0.8.

HY-P9970A

Infliximab (Anti-TNF-α) Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)	TNF Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .

HY-108831A

Natalizumab (Anti-CD49d) 3 Publications Verification AN100226; BG00002	Integrin	Inflammation/Immunology Cancer
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .

HY-P9979

Rozanolixizumab 1 Publications Verification UCB7665	TNF Receptor	Inflammation/Immunology
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .

HY-P99009

Batoclimab RVT-1401; HBM9161; IMVT-1401	Fc Receptor (FcR)	Inflammation/Immunology
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .

HY-P99570

Telazorlimab GBR-830	Inhibitory Antibodies	Inflammation/Immunology
Telazorlimab (GBR-830) is a humanized monoclonal antibody against OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for the research of autoimmune diseases .

HY-P99289

Epratuzumab Antibody hLL 2; AMG-412	CD22	Inflammation/Immunology Cancer
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .

HY-P991049

Atrosimab ATM-001	TNF Receptor	Metabolic Disease Inflammation/Immunology
Atrosimab is an Fv-Fc1K fusion protein with an EC₅₀ value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis .

HY-108829A

Abatacept (powder) 1 Publications Verification CTLA4lg (powder); BMS-188667 (powder); Orencia	CTLA-4	Inflammation/Immunology Cancer
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99670

Iscalimab CFZ-533; OM11-62MF	TNF Receptor	Metabolic Disease Inflammation/Immunology
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (K_D: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases .

HY-P99834

Crefmirlimab IAB22M2C; ImaginAb	Transmembrane Glycoprotein	Cancer
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., ⁸⁹Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research .

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	TNF Receptor	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .

HY-P99385

Vobarilizumab ALX-0061	Interleukin Related	Inflammation/Immunology
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (K_d: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .

HY-P99220

Tabalumab LY2127399	TNF Receptor	Inflammation/Immunology Cancer
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .

HY-P991567

VX5 VX5/5261	CXCR	Inflammation/Immunology Cancer
VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .

HY-P99414

Prezalumab AMG 557	Transmembrane Glycoprotein Interleukin Related	Inflammation/Immunology
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .

HY-108831

Natalizumab 3 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .

HY-P99563

Tibulizumab LY 3090106	TNF Receptor Interleukin Related	Inflammation/Immunology
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research .

HY-P99190

Eldelumab BMS-936557; MDX-1100	CXCR	Inflammation/Immunology
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .

HY-P99529

Valziflocept BAX1810; TAK-752; SM101	Fc Receptor (FcR)	Inflammation/Immunology
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE) .

HY-P990937

Pacibekitug PF-04236921; TOUR-006	Interleukin Related	Inflammation/Immunology
Pacibekitug (PF-04236921; TOUR-006) is a fully humanized IgG2 monoclonal antibody targeting IL-6. Pacibekitug binds to and neutralizes IL-6 signaling, thereby inhibiting the pathophysiological role of this pro-inflammatory cytokine in autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus) ^[1][2].

HY-P99638

Gefurulimab ALXN-1720	Complement System	Inflammation/Immunology
Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis .

HY-P991424

GSK2618960	Interleukin Related STAT	Inflammation/Immunology
GSK2618960 is a human monoclonal antibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used for the research of autoimmune and allergic inflammatory diseases. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99327

Tregalizumab BT-061	Inhibitory Antibodies	Inflammation/Immunology
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies .

HY-P991086

MGD010 PRV-3279	Fc Receptor (FcR)	Inflammation/Immunology
MGD010 (PRV-3279) is a bispecific antibody targeting CD32B (FcγRIIb) and CD79B. MGD010 transmits negative signals by simultaneously co-linking CD32B (FcγRIIb) with CD79B, a component of the B-cell receptor (BCR), thereby inhibiting activated B cells. MGD010 can be used in research related to autoimmune diseases .

HY-P99310

Perakizumab RG4934	Interleukin Related	Inflammation/Immunology
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .

HY-P991513

BI-655064	TNF Receptor	Inflammation/Immunology
BI-655064, a humanised anti-CD40 antibody with has fragment crystallisable (Fc) regions with two mutations that prevent Fc-mediated antibody-dependent or complement-mediated cellular cytotoxicity and platelet activation. BI-655064 can be used for the study of autoimmune disease, such as lupus nephritis and rheumatoid arthritis (RA) .

HY-163480

PF-06835375	CXCR	Inflammation/Immunology
PF-06835375 is a selective, humanized CXCR5-targeting immunoglobulin G1 antibody. PF-06835375 depletes CXCR5-positive B cells, follicular helper T cells and circulating Tfh-like cells. PF-06835375 is applicable to research related to autoimmune diseases .

HY-P991532

AT002 MEMD; EJ212/007-Cl2-5	ALCAM/CD166	Inflammation/Immunology Cancer
AT002 (CBAS-173, EJ212/007-Cl2-5) is a recombinant human IgG1 monoclonal antibody. AT002 targets the cell surface protein activated leukocyte adhesion molecule (ALCAM)/CD166. AT002 can be used in the research of cancer, autoimmune diseases and inflammatory diseases.

HY-P990262

Anti-Mouse CD8 Antibody (HB-129)	Transmembrane Glycoprotein	Metabolic Disease Inflammation/Immunology Cancer
Anti-Mouse CD8 Antibody (HB-129) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD8. Anti-Mouse CD8 Antibody (HB-129) can deplete CD8 ⁺ T cells. Anti-Mouse CD8 Antibody (HB-129) can be used for the researches of cancer, inflammation, immunology and metabolic disease, such as P815 tumor, experimental autoimmune thyroiditis (EAT) and graft versus host disease (GVHD) .

HY-P990808

Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1)	Interleukin Related	Infection Metabolic Disease Inflammation/Immunology Cancer
Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) is a rat-derived IgG2b κ type antibody inhibito, targeting to mouse CD122/IL-2Rβ. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can block IL-2 and IL-15. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can deplete natural killer (NK) cells and NKT cells. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can be used for the researches of cancer, infection, inflammation, immunology and metabolic disease, such as melanoma, experimental autoimmune encephalomyelitis (EAE) and diabetes .

HY-P991682

Emzotamig	TNF Receptor	Inflammation/Immunology
Emzotamig is a monoclonal antibody inhibitor targeting tumor necrosis factor (TNF). Emzotamig is promising for research of autoimmune diseases associated with TNF overexpression, such as rheumatoid arthritis and ankylosing spondylitis .

HY-P991658

Gerilimzumab ARGX-109; GB224; RYI-008	Interleukin Related	Inflammation/Immunology
Gerilimzumab (GB224) is a humanized monoclonal antibody inhibitor targeting interleukin-6 (IL-6). Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis .

HY-P991596

ANB004	Interleukin Related	Inflammation/Immunology
ANB004 is a humanized monoclonal antibody inhibitor, targeting IL-17. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research .

HY-P991274

BMS-986010	Interleukin Related	Inflammation/Immunology
BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). BMS-986010 reduces IL-23-induced STAT3 phosphorylation and inhibits Th17 cell differentiation and the release of proinflammatory cytokines (such as IL-17 and TNF-α). BMS-986010 is promising for research of autoimmune diseases such as psoriasis and Crohn's disease .

HY-P991477

HFB-100204	CXCR	Inflammation/Immunology
HFB-100204 is a human monoclonal antibody (mAb) targeting CXCR5. HFB-100204 reduces CXCR5+ immune cells, including B cells and Tfh cells, in the blood and spleen of hCXCR5 knockout mice. HFB-100204 can be used in autoimmune diseases research .

HY-P991655

AGS-009	IFNAR HIV	Infection Inflammation/Immunology
AGS-009 is a humanized monoclonal neutralising antibody targeting IFN-α. AGS-009 significantly reduces activated lymphocytes, such as CD4 ⁺ and CD8 ⁺ T cells as well as B cells in SIV infection rhesus macaque models. AGS-009 can be used for autoimmune diseases like systemic lupus erythematosus (SLE) and HIV infections research .

HY-P991725

Velvakiment ZL-1102	Interleukin Related	Inflammation/Immunology
Velvakiment is a humanized VHH nanobody that targets IL-17A. Velvakiment can be used for autoimmune diseases such as multiple sclerosis and rheumatoid arthritis research .

HY-P99893

Rozibafusp alfa AMG-570	CD28 TNF Receptor	Inflammation/Immunology
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Rozibafusp alfa can be used for the research of systemic lupus erythematosus and other autoimmune diseases .

HY-P991351

RTX-002	PD-1/PD-L1	Inflammation/Immunology
RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. RTX-002 can be used to study autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis .

HY-P990138

Anti-Monkey/Human CD20 Antibody (2H7)	CD20	Metabolic Disease Inflammation/Immunology
Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived IgG2b κ type antibody inhibitor, targeting to monkey/human CD20. Anti-Monkey/Human CD20 Antibody (2H7) specifically depletes B cells. Anti-Monkey/Human CD20 Antibody (2H7) can be used for the researches of inflammation and metabolic disease, such as diabetes and experimental autoimmune encephalomyelitis .

HY-P991275

CNTO4088	Interleukin Related	Inflammation/Immunology
CNTO4088 is a monoclonal antibody inhibitor targeting interleukin-23 (IL-23). CNTO4088 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .

HY-P991263

SCH-900117	Interleukin Related	Inflammation/Immunology
SCH-900117 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10574

Queuine 1 Publications Verification	Alkaloids Microorganisms Pyrrole Alkaloids Source Classification	Bacterial
Queuine is a selective substrate for tRNA guanine transglycosylase (TGT) and can be incorporated into eukaryotic tRNA. Queuine promotes tRNA modification, affecting mitochondrial function and Warburg metabolic phenotype. If Queuine is deficient, aerobic glycolysis can be enhanced, oxidative phosphorylation can be inhibited, and Warburg metabolism can be promoted, accompanied by increased ammonia and lactate production and increased lactate dehydrogenase activity. Queuine can be used for autoimmune diseases (such as experimental models of multiple sclerosis) and cancer metabolic regulation, and its deficiency is associated with low tRNA modification in tumor cells .

HY-N2335

Coumestrol Maximum Cited Publications 6 Publications Verification	Classification of Application Fields Leguminosae Glycine max (L.) merr Coumarins Phenols Polyphenols Phenylpropanoids Plants Disease Research Fields Source Classification Cancer	Estrogen Receptor/ERR
Coumestrol, a phytoestrogen present in soybean products, exhibits activities against cancers, neurological disorders, and autoimmune diseases. It suppresses proliferation of ES2 cells with an IC₅₀ of 50 μM.

HY-113037C

Farnesyl pyrophosphate ammonium Farnesyl diphosphate ammonium	Natural Products Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	TRP Channel Endogenous Metabolite Calcium Channel
Farnesyl pyrophosphate (Farnesyl diphosphate) ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases .

HY-P1680

Astin C Asterin	Natural Products Plants Compositae Erythrina latissima E. Mey. Source Classification	STING HSV
Astin C (Asterin) is a cyclopeptide that can be extracted from Aster tataricus. Astin C has anti-inflammatory and anti-cancer activities. Astin C can specifically inhibit the cGAS-STING signaling pathway, block the recruitment of IRF3 to the STING signalosome, and thus inhibit the innate inflammatory response. Astin C can be used in the research of autoimmune diseases and cancers .

HY-N2303

Eriocalyxin B 3 Publications Verification	Natural Products Classification of Application Fields Labiatae Senna sophera (L.) Roxb. Plants Inflammation/Immunology Disease Research Fields Source Classification	Apoptosis NF-κB Autophagy Reactive Oxygen Species (ROS) CDK PPAR FABP Akt mTOR
Eriocalyxin B is a diterpenoid compound that can be isolated from Chinese herb Isodon eriocalyx. Eriocalyxin B exhibits multiple activities, such as anti-cancer, anti-inflammatory, and inhibition of adipogenesis. Eriocalyxin B is capable of inducing apoptosis and autophagy in tumor cells. Eriocalyxin B can be used in the research of cancers, autoimmune diseases, and other conditions .

HY-N10574A

Queuine dihydrochloride 1 Publications Verification	Alkaloids Microorganisms Pyrrole Alkaloids Source Classification	Others
Queuine dihydrochloride is a selective substrate for tRNA guanine transglycosylase (TGT) and can be incorporated into eukaryotic tRNA. Queuine dihydrochloride promotes tRNA modification, affecting mitochondrial function and Warburg metabolic phenotype. If Queuine dihydrochloride is deficient, aerobic glycolysis can be enhanced, oxidative phosphorylation can be inhibited, and Warburg metabolism can be promoted, accompanied by increased ammonia and lactate production and increased lactate dehydrogenase activity. Queuine dihydrochloride can be used for autoimmune diseases (such as experimental models of multiple sclerosis) and cancer metabolic regulation, and its deficiency is associated with low tRNA modification in tumor cells .

HY-N10520

Pectic acid Methyl protopectin; Polygalacturonic acid	Natural Products Classification of Application Fields Rutaceae Plants Endogenous metabolite Citrus reticulata Blanco Human Gut Microbiota Metabolites Polysaccharides Microorganisms Inflammation/Immunology Disease Research Fields Saccharides Cancer Source Classification	Apoptosis Necroptosis Endogenous Metabolite
Pectic acid (Methyl protopectin), a polygalacturonic acid, induces cell apoptosis and necrosis in pituitary tumor cells. Pectic acid can be used in the research of cancers and autoimmune disease .

HY-N11286

Tridocosahexaenoylglycerol TG-DHA; Meganol D	Structural Classification Animals Lipid Source Classification	Others
Tridocosahexaenoylglycerol (TG-DHA) is an orally active dietary supplement that improves autoimmune encephalomyelitis in mice. Tridocosahexaenoylglycerol shows beneficial effects on neurodegenerative diseases and also improves macular function in diabetic retinopathy. Tridocosahexaenoylglycerol can be used for research on neurological diseases, inflammatory immune diseases, and metabolic diseases .

HY-N2335R

Coumestrol (Standard)	Structural Classification Leguminosae Glycine max (L.) merr Coumarins Phenols Polyphenols Phenylpropanoids Plants Source Classification	Reference Standards Estrogen Receptor/ERR
Coumestrol (Standard) is the analytical standard of Coumestrol. This product is intended for research and analytical applications. Coumestrol, a phytoestrogen present in soybean products, exhibits activities against cancers, neurological disorders, and autoimmune diseases. It suppresses proliferation of ES2 cells with an IC50 of 50 μM.

HY-13764A

dl-Tetrandrine	Alkaloids Stephania japonica var. discolor (Blume) Forman Plants Menispermaceae Alkaloid Dimers Source Classification	Calcium Channel
dl-Tetrandrine is an orally active and brain-penetrant calcium channel blocker that inhibits voltage-dependent calcium channels. dl-Tetrandrine selectively blocks Ca ²⁺ influx with an IC₅₀ value of approximately 1-10 μM. dl-Tetrandrine exerts anti-inflammatory, immunosuppressive, and anti-arrhythmic activities by inhibiting intracellular calcium overload, and can reverse multidrug resistance in tumor cells. dl-Tetrandrine is promising for research of autoimmune diseases (such as rheumatoid arthritis), cardiovascular diseases, and tumor drug resistance reversal .

HY-114341

Kaempferol 5-glucoside Kaempferol 5-O-β-D-glucopyranoside	Structural Classification Flavonols Flavonoids Plants Indigofera aspalathoides Vahl ex DC. Fabaceae Source Classification	Others
Kaempferol 5-glucoside (Kaempferol 5-O-β-D-glucopyranoside) is an orally active flavonol glycoside and immunomodulator. Kaempferol 5-glucoside is isolated from the aerial parts of Indigofera aspalathoides Vahl ex DC. Kaempferol 5-glucoside enhances delayed-type hypersensitivity in rats. Kaempferol 5-glucoside increases humoral antibody titers. Kaempferol 5-glucoside is used for the research of autoimmune diseases .

HY-N14737

Dunaimycin A1	Natural Products Microorganisms Source Classification	Fungal
Dunaimycin A1 is a 24-membered macrolide compound with immunosuppressive activity and antifungal activity against Aspergillus niger. Dunaimycin A1 is promising for research of autoimmune diseases .

Cat. No.	Product Name	Chemical Structure

HY-113037CS

Farnesyl pyrophosphate-d2 triammonium

Farnesyl pyrophosphate-d₂ (Farnesyl diphosphate-d₂) triammonium is a deuterium labeled Farnesyl pyrophosphate triammonium (HY-113037C). Farnesyl pyrophosphate ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

HY-177130S

Socrodeucitinib

Socrodeucitinib (Compound Example 58) is an orally active and selective tyrosine kinase 2 (TYK2) inhibitor with an IC₅₀ value of 1.41 nM. Socrodeucitinib exerts anti-inflammatory activity by inhibiting TYK2-mediated cytokine signaling pathways and reducing the secretion of inflammatory factors. Socrodeucitinib is promising for research of autoimmune diseases such as psoriasis and inflammatory diseases .

HY-144031S

Tyk2-IN-8
Tyk2-IN-8 (compound 3) is a selective Tyk-2 inhibitor with an IC₅₀ of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC₅₀ of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease .

HY-175310S

Voderdeucitinib
Voderdeucitinib (Compoudn I) is a TYK2 inhibitor with an anti-inflammatory activity. Voderdeucitinib can be used for inflammatory and autoimmune disease research, such as rheumatoid arthritis (RA), multiple sclerosis and intestinal bowel disease (IBD) .

HY-113037AS

Farnesyl pyrophosphate-d6

Farnesyl pyrophosphate-d₆ (Farnesyl diphosphate-d₆) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

HY-163314S

Tyk2-IN-18-d3
Tyk2-IN-18-d3 (Compound 18) is a Tyk2 inhibitor with an IC₅₀ value of < 30 nM for both IL-23 and IFNα. Tyk2-IN-18-d3 can be used for research on autoimmune diseases .

HY-163312S

Tyk2-IN-18-d5
Tyk2-IN-18-d5 (Compound 13) is the deuterated TYK2 inhibitor, targeting to JH2 domain. Tyk2-IN-18-d5 can be used for the research of inflammatory and autoimmune diseases .

HY-153951S

BTK-IN-26
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC₅₀ values of 0.7 and 0.8 nM for BTK and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .

HY-135810S

Cletoquine-d4

Cletoquine-d₄ is deuterium labeled Cletoquine. Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine has antimalarial effects and has the potential for autoimmune diseases treatment .

HY-135810S1

Cletoquine-d4-1

Cletoquine-d₄-1 is the deuterium labeled Cletoquine. Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine has antimalarial effects and has the potential for autoimmune diseases treatment .

HY-10405S

Pamapimod-d4

Pamapimod-d₄ (Ro4402257-d₄) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC₅₀s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .

HY-W777442

Cletoquine-d4 Oxalate

Cletoquine-d₄ Oxalate is the deuterium labeled Cletoquine (oxalate) (HY-135810A). Cletoquine oxalate (Desethylhydroxychloroquine oxalate) is a major active metabolite of Hydroxychloroquine. Cletoquine oxalate is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine oxalate is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine oxalate has antimalarial effects and has the potential for autoimmune diseases treatment .

HY-B1451S

Imidapril-d3 hydrochloride

Imidapril-d₃ hydrochloride (TA-6366-d₃) is the deuterium labeled Imidapril hydrochloride. Imidapril hydrochloride (TA-6366) is an orally active dual inhibitor of angiotensin-converting enzyme (ACE) and MMP-9. Imidapril hydrochloride inhibits lipopolysaccharide-induced phosphorylation of c-Jun, MKK4 and JNK in monocytes, and downregulates the production of specific inflammatory factors such as TNF-α and IP-10, thereby exerting anti-inflammatory activity. Imidapril hydrochloride also effectively ameliorates mesangial expansion and reduces urinary albumin excretion by inhibiting angiotensin AngII production, lowering glomerular pressure and oxidative stress, thus delaying disease progression. Imidapril hydrochloride can also directly bind to the active site of MMP-9 to inhibit gelatinase activity, and suppress the enlargement of cerebral aneurysms without altering systemic blood pressure. Imidapril hydrochloride is widely applicable to related studies on autoimmune glomerulonephritis, diabetic nephropathy, cerebral aneurysms and other conditions .

HY-166594S

Deucravacitinib-13C,d3

Deucravacitinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis .

Cat. No.	Product Name		Classification

HY-108039

Bezisterim HE 3286; NE-3107		Alkynes
Bezisterim (HE 3286; NE-3107) is a synthetic derivative of a natural anti-inflammatory steroid, β-AET. Bezisterim is an orally active partial NF-κB inhibitor. HE3286 reduces proinflammatory signals, including IL-6 and matrix metallopeptidase 3. Bezisterim freely penetrates the blood brain barrier in mice. Bezisterim can be used for the research of the ulcerative colitis, arthritis, experimental autoimmune encephalomyelitis . Bezisterim is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-176566

H-151 Alkyne		Alkynes
H-151 Alkyne (Compound H-151-AL) is a selective STING (Stimulator of interferon genes) inhibitor. H-151 Alkyne is promising for research of autoimmune diseases such as systemic lupus erythematosus, scleroderma, and autoinflammatory diseases .

HY-148908

TNF-α-IN-8		Azide
TNF-α-IN-8 (compound I-42) is a TNF-α inhibitor. TNF-α-IN-8 is an isoindole-imide compound. TNF-α-IN-8 can be used for the research of cancer, heart disease, osteoporosis, inflammatory, allergic and autoimmune diseases . TNF-α-IN-8 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-112946

LU-001i		Azide
LU-001i is a highly specific proteasome β1i (LMP2) inhibitor. LU-001i alone has no significant immunomodulatory effect, but when combined with the LMP7 inhibitor (PRN1126), it can exert anti-inflammatory and immunomodulatory effects. LU-001i can be used for the study of autoimmune diseases .

Cat. No.	Product Name		Classification

HY-150751

ODN TTAGGG 3 Publications Verification ODN A151		CpG ODNs
ODN TTAGGG (ODN A151), an inhibitory oligonucleotide (ODN), is a TLR9, AIM2, and cGAS antagonist. ODN TTAGGG inhibits AIM2 inflammasome activation and cGAS activation through competition with DNA. ODN TTAGGG blocks AIM2-mediated Pyroptosis and inhibits IL-18 production. ODN TTAGGG has immunosuppressive effects and can be used in research on related autoimmune diseases such as lupus erythematosus . ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3'.

HY-150751C

ODN TTAGGG sodium 3 Publications Verification ODN A151 sodium		CpG ODNs
ODN TTAGGG sodium, inhibitory oligonucleotide (ODN), is a TLR9, AIM2 and cGAS antagonist. ODN TTAGGG sodium is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG sodium can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3' .

HY-154974

LNP Lipid-8		Cationic Lipids
LNP Lipid-8 (11-A-M) is an ionizable single-tail multi-head lipid that can be used as a lipid nanoparticle (LNP) to deliver siRNA to T cells without targeting ligands. LNP Lipid-8 is more selective for T cells than other cell types such as hepatocytes. LNP Lipid-8 selectively delivers siRNA/sgRNA to T cells (especially CD8+ T cells) through endogenous lipid transport pathways, and can enter cells and release RNA through endocytosis to achieve gene silencing. LNP Lipid-8 loaded with GFP siRNA (siGFP) significantly led to GFP gene silencing in mouse models. LNP Lipid-8 showed good efficacy and safety in both cells and animals, without obvious liver targeting and toxicity. LNP Lipid-8 can be used for RNA delivery research in the fields of tumor immunotherapy and T cell-mediated autoimmune diseases .

HY-W409806

Cholesterylamine		Cholesterol
Cholesterylamine is a cationic lipid. Cholesterylamine can be added to the PLGA to prepare PLGA particle having surface charge. Cholesterylamine can be used for drug delivery. Cholesterylamine can be used for autoimmune diseases and allergy research .

HY-160577

DOG-IM4		Cationic Lipids
DOG-IM4 can be used to synthesize nanoparticles to deliver antigen-encoding nucleic acids. It could be used to try to target autoimmune diseases, rare blood or metabolic diseases, allergies, cancer or infectious diseases .

HY-171984

514O6,10		Cationic Lipids
514O6,10 is an ionizable lipidoid containing a branched-tail. 514O6,10 can be used to synthesize lipid nanoparticles (LNPs) for delivering mRNA to natural killer and dendritic cells within the lung. 514O6,10 can be used for the RNA therapies for lung diseases associated with immune cell dysregulation, including cancer, viral infections, and autoimmune disorders research .

HY-174633

Human IL17A mRNA		mRNA Interleukin & Receptors
Human IL17A mRNA encodes the human interleukin 17A (IL17A) protein, a member of the IL-17 receptor family. IL17A plays a pivotal role in various infectious diseases, inflammatory and autoimmune disorders, and cancer.

HY-174600

Human IL6 mRNA		mRNA Interleukin & Receptors
Human IL6 mRNA encodes the human interleukin 6 (IL6) protein, a cytokine that functions in inflammation and the maturation of B cells. IL6 has been shown to be an endogenous pyrogen capable of inducing fever in people with autoimmune diseases or infections. The functioning of this gene is implicated in a wide variety of inflammation-associated disease states, including suspectibility to diabetes mellitus and systemic juvenile rheumatoid arthritis.

HY-174632

Human IL17RA mRNA		mRNA Interleukin & Receptors
Human IL17RA mRNA encodes the human interleukin 17 receptor subunit alpha (IL17RA) protein, a ubiquitous type I membrane glycoprotein that binds with low affinity to interleukin 17A. Interleukin 17A and its receptor play a pathogenic role in many inflammatory and autoimmune diseases such as rheumatoid arthritis.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Autoimmune diseases

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products